HTL to Invest in Production Facility for Injectable Grade Sodium Hyaluronate
The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times.
HTL, a hyaluronic acid and biopolymer solutions supplier based in France, announced it will invest in a production facility for injectable grade sodium hyaluronate production. Financial details of the investment were not disclosed.
The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times by 2021, the company said in an Oct. 30, 2019 press release. It will also boost the global marketing of the company’s medical applications and biopolymer-based innovation.
“This new, unprecedented capacity investment demonstrates the long-term commitment of HTL and its shareholders to anticipate and fulfill the growing needs of its customers worldwide,” said Yvon Bastard, CEO of HTL, in the press release.
HTL will be exhibiting at CPhI Worldwide from Nov. 5–7, 2019 at stand 4.2G13.
Source: HTL
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
